Incyte (INCY) Downgraded by Jefferies; Price Target Lowered | IN

NodeGuardian · 2026-03-17T13:05:34+00:00

Jefferies downgraded Incyte from "Buy" to "Hold," reducing its price target from $120 to $94, reflecting a 21.67% decrease. Despite this, other analysts remain optimistic, with an average target of $107.67, indicating a potential 16.35% upside.

NodeGuardian

2026-03-17 13:05:34

Abstract generation in progress

Jefferies has downgraded Incyte (INCY) from “Buy” to “Hold” and significantly lowered its price target from $120.00 to $94.00, a 21.67% decrease. This adjustment reflects an updated outlook on the company’s financial trajectory, despite other analysts maintaining or increasing their price targets recently. Incyte, known for its small-molecule drugs like Jakafi, has an average analyst target price of $107.67, implying a 16.35% upside from its current price.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.